
In a Q&A, Florin Draica, MD, MBA, explains the 72-hour PEP window for ensitrelvir, breakthrough infection data, and which patients to prioritize.

Florin Draica, MD, MBA, is the US VP of medical affairs at Shionogi.

In a Q&A, Florin Draica, MD, MBA, explains the 72-hour PEP window for ensitrelvir, breakthrough infection data, and which patients to prioritize.